ArticleScientific reports2019
Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Coagulation Risk Prediction in Patients With Liver Failure: Integrated Meta-Analysis and Machine Learning Model Study.JMIR medical informatics · 2025Pooled it
- Extracorporeal liver support systems in patients with acute-on-chronic liver failure: An updated systematic review and meta-analysis.Artificial organs · 2025Pooled it
- A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system.Scientific reports · 2021Trial
- Neutrophil Percentage to Albumin Ratio Is Associated With In-Hospital Mortality in Patients With Acute Type A Aortic Dissection.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Association between volume of processed plasma and total bilirubin reduction during plasma adsorption for severe liver disease.European journal of medical research · 2025Observational
- Machine learning-based algorithms for the prediction of 90-day survival in patients with liver failure receiving artificial liver therapy.Frontiers in physiology · 2025Article
- Outcome of patients with different stages of acute-on-chronic liver failure treated with artificial liver support system.Frontiers in medicine · 2024Article
- Screening and evaluation of key technologies for non-bioartificial liver care: an empirical study.Frontiers in medicine · 2024Article
- Mixed mode of artificial liver support in patients with acute-on-chronic liver failure: a retrospective cohort study.Hepatology international · 2023Article
- [Research progress of non-biological artificial liver support system therapy for paitents with liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- A novel nomogram to predict 90-day mortality in patients with hepatitis B virus-related acute-on-chronic liver failure: a single-center retrospective study.BMC gastroenterology · 2023Article
- Assessing the length of hospital stay for patients with myasthenia gravis based on the data mining MARS approach.Frontiers in neurology · 2023Article
- Lower level of IL-28A as a predictive index of the artificial liver support system in effective treatment of patients with HBV-ACLF.Journal of clinical laboratory analysis · 2022Article
- The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- [Effect of artificial liver with double plasma molecular absorb system model on patients' platelets and corresponding treatment strategy].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022Article
- Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives.Stem cell research & therapy · 2022Review
- Design for a Multicentre Prospective Cohort for the Assessment of Platelet Function in Patients with Hepatitis-B-Virus-Related Acute-on-Chronic Liver Failure.Clinical epidemiology · 2022Article
- Establishment of a risk assessment score for deep vein thrombosis after artificial liver support system treatment.World journal of clinical cases · 2021Article
- Review
- Stem cell therapy in coronavirus disease 2019: current evidence and future potential.Cytotherapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Artificial liver support systems (ALSS) are widely used to treat patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). The aims of the present study were to investigate the subgroups of patients with HBV-ACLF who may benefit from ALSS therapy, and the relevant patient-specific factors. 489 ALSS-treated HBV-ACLF patients were enrolled, and served as derivation and validation cohorts for classification and regression tree (CART) analysis. CART analysis identified three factors prognostic of survival: hepatic encephalopathy (HE), prothrombin time (PT), and total bilirubin (TBil) level; and two distinct risk groups: low (28-day mortality 10.2-39.5%) and high risk (63.8-91.1%). The CART model showed that patients lacking HE and with a PT ≤ 27.8 s and a TBil level ≤455 μmol/L experienced less 28-day mortality after ALSS therapy. For HBV-ACLF patients with HE and a PT > 27.8 s, mortality remained high after such therapy. Patients lacking HE with a PT ≤ 27.8 s and TBil level ≤ 455 μmol/L may benefit markedly from ALSS therapy. For HBV-ACLF patients at high risk, unnecessary ALSS therapy should be avoided. The CART model is a novel user-friendly tool for screening HBV-ACLF patient eligibility for ALSS therapy, and will aid clinicians via ACLF risk stratification and therapeutic guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.